Knockout of SOD1 alters murine hepatic glycolysis, gluconeogenesis, and lipogenesis
- PMID: 22974764
- PMCID: PMC3472123
- DOI: 10.1016/j.freeradbiomed.2012.08.570
Knockout of SOD1 alters murine hepatic glycolysis, gluconeogenesis, and lipogenesis
Abstract
We previously observed a stronger effect of knockout of Cu,Zn-superoxide dismutase (SOD1) than that of Se-dependent glutathione peroxidase 1 (GPX1) on murine body weight and glucose homeostasis. Two experiments were conducted to determine how hepatic lipid profiles and key metabolic regulators were correlated with this difference. SOD1(-/-) and GPX1(-/-) mice and their respective wild-type (WT) littermates (n=6 or 7/group, male) were fed a Se-adequate Torula yeast-sucrose diet and killed at 6 months of age to collect liver samples. In Experiment 1, fasted SOD1(-/-) mice displayed pyruvate intolerance and a 61% decrease (P<0.05) in liver glycogen compared with their WT littermates. The former had lower (P<0.05) activities of phosphoenolpyruvate carboxykinase, total protein phosphatase, and protein phosphatase 2A, but a higher (P<0.05) activity of glucokinase in the liver than the latter. In contrast, hepatic concentrations of total cholesterol, triglycerides, and nonesterified fatty acids were increased by 11 to 100% (P<0.05) in the SOD1(-/-) mice. Meanwhile, these mice had elevated (P<0.05) hepatic protein levels of sterol-regulatory element binding proteins 1 and 2, p53 MAPK, total and phosphorylated AMP-activated protein kinase α1 protein, protein tyrosine phosphatase 1B, and protein phosphatase 2B. In Experiment 2, GPX1(-/-) mice and their WT littermates were compared, but showed no difference in any of the measures. In conclusion, knockout of SOD1, but not GPX1, led to a decreased liver glycogen storage synchronized with pyruvate intolerance and elevated hepatic lipid profiles in adult mice. This striking comparison was possibly due to unique impacts of these two knockouts on intracellular tone of H(2)O(2) and key regulators of liver gluconeogenesis, glycolysis, and lipogenesis.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures







Similar articles
-
Lipopolysaccharide-induced hepatic oxidative injury is not potentiated by knockout of GPX1 and SOD1 in mice.Biochem Biophys Res Commun. 2011 Jan 7;404(1):559-63. doi: 10.1016/j.bbrc.2010.12.025. Epub 2010 Dec 8. Biochem Biophys Res Commun. 2011. PMID: 21145306 Free PMC article.
-
Knockouts of SOD1 and GPX1 exert different impacts on murine islet function and pancreatic integrity.Antioxid Redox Signal. 2011 Feb 1;14(3):391-401. doi: 10.1089/ars.2010.3302. Epub 2010 Sep 29. Antioxid Redox Signal. 2011. PMID: 20586612 Free PMC article.
-
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c.Cell Metab. 2012 May 2;15(5):725-38. doi: 10.1016/j.cmet.2012.03.015. Epub 2012 Apr 19. Cell Metab. 2012. PMID: 22521878
-
Selenium and diabetes--evidence from animal studies.Free Radic Biol Med. 2013 Dec;65:1548-1556. doi: 10.1016/j.freeradbiomed.2013.07.012. Epub 2013 Jul 16. Free Radic Biol Med. 2013. PMID: 23867154 Free PMC article. Review.
-
Interference of selenium and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism.Free Radic Biol Med. 2013 Dec;65:1538-1547. doi: 10.1016/j.freeradbiomed.2013.07.016. Epub 2013 Jul 18. Free Radic Biol Med. 2013. PMID: 23872396 Review.
Cited by
-
Paradoxical Roles of Antioxidant Enzymes: Basic Mechanisms and Health Implications.Physiol Rev. 2016 Jan;96(1):307-64. doi: 10.1152/physrev.00010.2014. Physiol Rev. 2016. PMID: 26681794 Free PMC article. Review.
-
Disrupting SOD1 activity inhibits cell growth and enhances lipid accumulation in nasopharyngeal carcinoma.Cell Commun Signal. 2018 Jun 11;16(1):28. doi: 10.1186/s12964-018-0240-3. Cell Commun Signal. 2018. PMID: 29891006 Free PMC article.
-
Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models.Int J Mol Sci. 2023 Jun 10;24(12):9996. doi: 10.3390/ijms24129996. Int J Mol Sci. 2023. PMID: 37373143 Free PMC article. Review.
-
FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.Front Endocrinol (Lausanne). 2020 Dec 14;11:601290. doi: 10.3389/fendo.2020.601290. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33381084 Free PMC article. Review.
-
SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis.Brain. 2019 Aug 1;142(8):2230-2237. doi: 10.1093/brain/awz182. Brain. 2019. PMID: 31332433 Free PMC article.
References
-
- Fonseca VA. The metabolic syndrome, hyperlipidemia, and insulin resistance. Clin Cornerstone. 2005;7:61–72. - PubMed
-
- Ross R, Aru J, Freeman J, Hudson R, Janssen I. Abdominal adiposity and insulin resistance in obese men. Am. J. Physiol. Endocrinol. Metab. 2002;282:E657–E663. - PubMed
-
- Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J. Intern. Med. 1990;227:273–278. - PubMed
-
- Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005;143:722–728. - PubMed
-
- Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am. J. Clin. Nutr. 2006;83:1248–1251. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous